Porton Pharma Solutions Ltd. (300363.SZ) Plans to Acquire Partial Stake in Yifeng Yunding Fund

Stock News12-17

Porton Pharma Solutions Ltd. (300363.SZ) announced its intention to acquire a partial stake in Shenzhen Yifeng Yunding Venture Capital Partnership (LP) (referred to as "Yifeng Yunding Fund") held by Chen Yanxi for a nominal consideration of RMB 1. Upon completion of the acquisition, the company will fulfill its capital contribution obligation of RMB 20 million in accordance with the partnership agreement.

Yifeng Yunding Fund specializes in investing in Hangzhou Yifeng Runjun Venture Capital Partnership (LP) (referred to as "Yifeng Runjun Fund"). Through this investment, Porton Pharma Solutions will gain indirect exposure to Yifeng Runjun Fund. Shenzhen Yifeng Investment Management Enterprise (LP) is one of China's earliest professional investment institutions focused on the biopharmaceutical sector, with expertise in global biopharmaceutical investments.

This strategic move aims to leverage the high-quality resources of professional investment institutions to facilitate business expansion, client acquisition, and the introduction of strategic resources for Porton Pharma Solutions. Yifeng Runjun Fund primarily invests in innovative drugs, high-end medical devices, biotech companies, and other high-potential enterprises in the healthcare sector, both domestically and internationally. The investments may create synergistic opportunities for collaboration with Porton Pharma Solutions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186068646?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186068646","market":"sh","top_or_hot":-1,"title":"Porton Pharma Solutions Ltd. (300363.SZ) Plans to Acquire Partial Stake in Yifeng Yunding Fund","media":"Stock News","content":"<p>Porton Pharma Solutions Ltd. (300363.SZ) announced its intention to acquire a partial stake in Shenzhen Yifeng Yunding Venture Capital Partnership (LP) (referred to as \"Yifeng Yunding Fund\") held by Chen Yanxi for a nominal consideration of RMB 1. Upon completion of the acquisition, the company will fulfill its capital contribution obligation of RMB 20 million in accordance with the partnership agreement.</p>\n<p>Yifeng Yunding Fund specializes in investing in Hangzhou Yifeng Runjun Venture Capital Partnership (LP) (referred to as \"Yifeng Runjun Fund\"). Through this investment, Porton Pharma Solutions will gain indirect exposure to Yifeng Runjun Fund. Shenzhen Yifeng Investment Management Enterprise (LP) is one of China's earliest professional investment institutions focused on the biopharmaceutical sector, with expertise in global biopharmaceutical investments.</p>\n<p>This strategic move aims to leverage the high-quality resources of professional investment institutions to facilitate business expansion, client acquisition, and the introduction of strategic resources for Porton Pharma Solutions. Yifeng Runjun Fund primarily invests in innovative drugs, high-end medical devices, biotech companies, and other high-potential enterprises in the healthcare sector, both domestically and internationally. The investments may create synergistic opportunities for collaboration with Porton Pharma Solutions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Porton Pharma Solutions Ltd. (300363.SZ) Plans to Acquire Partial Stake in Yifeng Yunding Fund</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPorton Pharma Solutions Ltd. (300363.SZ) Plans to Acquire Partial Stake in Yifeng Yunding Fund\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-17 17:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Porton Pharma Solutions Ltd. (300363.SZ) announced its intention to acquire a partial stake in Shenzhen Yifeng Yunding Venture Capital Partnership (LP) (referred to as \"Yifeng Yunding Fund\") held by Chen Yanxi for a nominal consideration of RMB 1. Upon completion of the acquisition, the company will fulfill its capital contribution obligation of RMB 20 million in accordance with the partnership agreement.</p>\n<p>Yifeng Yunding Fund specializes in investing in Hangzhou Yifeng Runjun Venture Capital Partnership (LP) (referred to as \"Yifeng Runjun Fund\"). Through this investment, Porton Pharma Solutions will gain indirect exposure to Yifeng Runjun Fund. Shenzhen Yifeng Investment Management Enterprise (LP) is one of China's earliest professional investment institutions focused on the biopharmaceutical sector, with expertise in global biopharmaceutical investments.</p>\n<p>This strategic move aims to leverage the high-quality resources of professional investment institutions to facilitate business expansion, client acquisition, and the introduction of strategic resources for Porton Pharma Solutions. Yifeng Runjun Fund primarily invests in innovative drugs, high-end medical devices, biotech companies, and other high-potential enterprises in the healthcare sector, both domestically and internationally. The investments may create synergistic opportunities for collaboration with Porton Pharma Solutions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1186068646","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186068646","pubTimestamp":1765964339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Porton Pharma Solutions Ltd. (300363.SZ) announced its intention to acquire a partial stake in Shenzhen Yifeng Yunding Venture Capital Partnership (LP) (referred to as \"Yifeng Yunding Fund\") held by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300363":"博腾股份","BK0239":"医药制造","BK0028":"国家队"},"translate_title":"Porton Pharma Solutions Ltd.(300363.SZ)拟收购益丰云顶基金部分股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300363":1},"content_text":"Porton Pharma Solutions Ltd. (300363.SZ) announced its intention to acquire a partial stake in Shenzhen Yifeng Yunding Venture Capital Partnership (LP) (referred to as \"Yifeng Yunding Fund\") held by Chen Yanxi for a nominal consideration of RMB 1. Upon completion of the acquisition, the company will fulfill its capital contribution obligation of RMB 20 million in accordance with the partnership agreement.\nYifeng Yunding Fund specializes in investing in Hangzhou Yifeng Runjun Venture Capital Partnership (LP) (referred to as \"Yifeng Runjun Fund\"). Through this investment, Porton Pharma Solutions will gain indirect exposure to Yifeng Runjun Fund. Shenzhen Yifeng Investment Management Enterprise (LP) is one of China's earliest professional investment institutions focused on the biopharmaceutical sector, with expertise in global biopharmaceutical investments.\nThis strategic move aims to leverage the high-quality resources of professional investment institutions to facilitate business expansion, client acquisition, and the introduction of strategic resources for Porton Pharma Solutions. Yifeng Runjun Fund primarily invests in innovative drugs, high-end medical devices, biotech companies, and other high-potential enterprises in the healthcare sector, both domestically and internationally. The investments may create synergistic opportunities for collaboration with Porton Pharma Solutions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186068646","isCrawlerRequest":true}